Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $187 | In Stock | |
5 mg | $414 | In Stock | |
10 mg | $595 | In Stock | |
25 mg | $882 | In Stock | |
50 mg | $1,180 | In Stock | |
100 mg | $1,600 | In Stock | |
1 mL x 10 mM (in DMSO) | $588 | In Stock |
Description | Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells. |
Targets&IC50 | BCL-XL:5.9 nM, BCL2:2 nM |
In vitro | Lisaftoclax shows IC50s of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4 11 cells and Bcl-xl dependent Molm 13 cells[1]. |
Alias | Bcl-2/Bcl-xl inhibitor 1, APG-2575 |
Molecular Weight | 882.42 |
Formula | C45H48ClN7O8S |
Cas No. | 2180923-05-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (51 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.